Search results
Salmonella Vaccine Study in Oxford is a first-in-human study of a novel vaccine against invasive non-typhoidal Salmonellosis (iNTS), a neglected disease largely affecting low- and middle-income countries.
The glycoconjugate strategy for new Salmonella vaccines is principally an antibody approach. The majority of Salmonella conjugate vaccines employ the familiar carrier proteins, tetanus toxoid (TT), diphtheria toxoid (DT) and the nontoxic recombinant form of diphtheria toxin (CRM 197), as well as the less-commonly used protein, rEPA.
In this review we focus on (1) recent advances in live attenuated Salmonella vaccine development, (2) improvements in expression of foreign antigens in carrier vaccines and (3) adaptation of attenuated strains as sources of purified antigens and vesicles that can be used for subunit and conjugate vaccines or together with attenuated vaccine ...
30 wrz 2024 · Effective vaccines against Salmonella-related diseases must stimulate both humoral immunity to combat extracellular bacteria and cellular immunity to eliminate intracellular pathogens. This multifaceted strategy is vital for effectively addressing Salmonella infections.
14 lis 2023 · Method and analysis: The Salmonella Vaccine Study in Oxford is a randomised placebo-controlled participant-observer blind phase I study of the iNTS-GMMA vaccine.
KEY CONSIDERATIONS FOR THE DEVELOPMENT OF SALMONELLA VACCINES. Antibodies are an essential component of the protective immune response to Salmonella. An ideal vaccine would therefore be the one able to induce both antibody responses and protective cellular immunity.
12 paź 2018 · Thanks to new research from Professor Andrew Pollard ’s Oxford team, published in September in Clinical Infectious Diseases, researchers have taken a step towards answering this question, and their results suggest that some vaccines might provide herd immunity. The culprit is found in poo.
